Kadcyla is ananti-cancer medication which will prevents the growth and spread of cancer cells in the body
Emtansine is known as MCC-DM1 complex.
Kadcyla is well defined as recombinant monoclonal antibody product by mammalian cells and DM1 and MCC produced by chemical synthesis.
Kadcyla is normally used after other chemo drugs have been tried and failed to give success.
160mg per vial
Kadcyla is a single component which indicated for the treatment of HER-2positive metastatic breast cancer, the treatment given for who previously received trastuzumab and a taxane in combination or alone treatment. Patients have either two conditions
1. Previously got treatment for metastatic disease
2. Relapsed during or within six months of completing adjuvant therapy
Mechanism of action
Ado-trastuzumab emtansine is a type of HER2-antibody drug conjugate which consolidated the HER2 aimed actions of trastuzumab with the microtubule inhibitor DM1 (a maytansine derivative).
The conjugate, which is joined through a stable thioether linker, allows for selective delivery into HER2 overexpressing cells, resulting in cell cycle arrest and apoptosis
Kadcyla recommended dose for adult dose is 3.6mg/kg administer every 3 weeks (21-day cycle).
Treatment received until disease progression or unacceptable toxicity
More than 3.6mg/kg dose should not administer to the patients
Do not substitute other medicine for kadcyla or with trastuzumab
Administer kadcyla injection over 90minutes in first infusion.
Followed by subsequent infusions over 30 minutes.
Kadcyla help to prevent breast cancer in which it may cause some serious and common side effects. Inform your doctor If any of these signs or symptoms occurs or do not cure soon.
Common side effects :
• Stomach upset
• Mouth ulcer, throat ulcer
• Dry mouth
• Joint or muscle pain
• Dry, red or teary eyes
• Vision blurred
Some serious side effects :
• Where the medication was injected in the place Pain, itching, redness, swelling, blisters, or sores.
• Nosebleeds and other unusual bleeding or bruising
• Bloody or black, tarry stools
• In the hands or feet pain, burning or tingling
• Breathing difficulty.
Severe hepatotoxicity, which involves in liver failure and death has been identified. Transaminases and bilirubin at baseline and prior to each dose should be monitor, If dose increases then require dose reduction or discontinuation.
Left ventricular dysfunction:
During treatment, evaluate the function of left ventricular function before or at least every 3 months. If any significant function of left ventricular decreases, then withhold the kadcyla treatment
When kadcyla administer to pregnant women it will cause harm to the patients. Based on its mechanism of action, the antibody and cytotoxic components of kadcyla will cause embryo-fetal toxicity
Permanently discontinue kadcyla treatment in patients having ILD or pneumonitis